Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

The Rubenstein School for Environment and Natural Resources just welcomed in over 270 first-year students, their largest first-year class ever.

ENV-294 is a clinical-stage small molecule designed to address the shared pathways underlying multiple inflammatory conditions via a first-in-class mechanism. ENV-294 entered Phase 1 studies in ...